ReviewJournal of inflammation research2026
Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that impairs health-related quality of life. Although omalizumab is a cornerstone treatment for patients uncontrolled with up-dosed second-generation H1-antihistamines, some patients remain partially responsive or refractory. This narrative review summarizes current concepts in defining, predicting, and managing omalizumab-refractory CSU. Response assessment should rely on validated patient-reported outcome measures, particularly the 7-day Urticaria Activity Score (UAS7) and Urticaria Control Test (UCT), to distinguish complete response, partial response, and true non-response, while also helping to identify pseudo-resistance related to poor adherence or misdiagnosis. Emerging biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associated with type I autoallergic CSU and a better response to omalizumab, whereas low total IgE, basopenia, positive basophil histamine release assay (BHRA) or basophil activation test (BAT) results, and other autoimmune markers suggest type IIb autoimmune CSU and a greater likelihood of inadequate anti-IgE response. For patients with persistent disease despite omalizumab, cyclosporine A remains an evidence-based option, while newer targeted therapies, including dupilumab, Bruton's tyrosine kinase inhibitors, and anti-KIT antibodies, are expanding the treatment landscape. Overall, management of omalizumab-refractory CSU is shifting toward precision medicine that integrates validated outcome measures, biomarker-informed endotyping, comorbidities, access, safety, and patient preferences. However, standardized switching algorithms, comparative effectiveness data, and validated predictive biomarkers are still needed to optimize individualized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.